IGFBP-7產(chǎn)品信息
別稱:IBP7,IGFBP7
物種:Human
屬性:Protein
標(biāo)記:Biotin-labeled/Unconjugated
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

IGFBP-7用戶評(píng)價(jià)

IGFBP-7分子背景
胰島素樣生長因子結(jié)合蛋白7(IGFBP7)也稱為IGFBP-rP1、MAC25蛋白、PGI2刺激因子、前列環(huán)素刺激因子和腫瘤源性粘附因子,它包含一個(gè)Ig樣C2型(免疫球蛋白樣)結(jié)構(gòu)域、一個(gè)IGFBP N端結(jié)構(gòu)域和一個(gè)Kazal樣結(jié)構(gòu)域。IGFBP7的主要功能是調(diào)節(jié)組織中胰島素樣生長因子(IGFs)的可用性,以及調(diào)節(jié)IGF與其受體的結(jié)合。IGFBP7以高親和力結(jié)合IGF,但IGF-I和IGF-II除外。IGFBP7還刺激細(xì)胞粘附。此外,IGFBP7與某些癌癥有關(guān)。

關(guān)鍵字: IGFBP7;IGFBP7蛋白;IBP7蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。